These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 25650710)
1. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome. Gianniou C; Dirani A; Jang L; Mantel I Retina; 2015 Jun; 35(6):1195-201. PubMed ID: 25650710 [TBL] [Abstract][Full Text] [Related]
2. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101 [TBL] [Abstract][Full Text] [Related]
3. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Brown DM; Chen E; Mariani A; Major JC; Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717 [TBL] [Abstract][Full Text] [Related]
4. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Jang L; Gianniou C; Ambresin A; Mantel I Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1211-6. PubMed ID: 25267418 [TBL] [Abstract][Full Text] [Related]
5. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Bloch SB; Lund-Andersen H; Sander B; Larsen M Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150 [TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050 [TBL] [Abstract][Full Text] [Related]
7. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
8. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion. Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942 [TBL] [Abstract][Full Text] [Related]
9. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073 [TBL] [Abstract][Full Text] [Related]
10. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G; Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488 [TBL] [Abstract][Full Text] [Related]
11. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838 [TBL] [Abstract][Full Text] [Related]
12. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309 [TBL] [Abstract][Full Text] [Related]
14. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691 [TBL] [Abstract][Full Text] [Related]
15. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Major JC; Wykoff CC; Mariani AF; Chen E; Croft DE; Brown DM Retina; 2014 Jan; 34(1):48-54. PubMed ID: 23764967 [TBL] [Abstract][Full Text] [Related]
16. Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab. Grenga PL; Fragiotta S; Meduri A; Lupo S; Marenco M; Vingolo EM Can J Ophthalmol; 2013 Oct; 48(5):394-9. PubMed ID: 24093186 [TBL] [Abstract][Full Text] [Related]
17. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692 [TBL] [Abstract][Full Text] [Related]
18. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255 [TBL] [Abstract][Full Text] [Related]
19. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. Waldstein SM; Philip AM; Leitner R; Simader C; Langs G; Gerendas BS; Schmidt-Erfurth U JAMA Ophthalmol; 2016 Feb; 134(2):182-90. PubMed ID: 26661463 [TBL] [Abstract][Full Text] [Related]
20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]